Qureight Raises $20 Mn Series B to Expand AI-Powered Medical Imaging for Clinical Trials

Qureight will use the new funding to expand its 3D AI-powered medical imaging technology and grow its business. The company plans to meet increasing demand for advanced imaging solutions in clinical trials focused on lung and heart diseases.

According to Dr Muhunthan Thillai, MD, PhD, Co-founder and CEO, Qureight: “We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors. I also welcome Anna Salim of Hargreave Hale to the Board, and thank all of our existing investors who participated in this round. Their ongoing support reflects the confidence in both our enterprise-grade imaging platform, and our world-class team to address a critical demand to accelerate clinical trials.”

Dr Inga Deakin PhD, Partner, Molten Ventures, added: “Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team’s rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation.”

Qureight is a healthcare technology company that uses artificial intelligence (AI) and advanced medical imaging to support clinical trials and medical research. The company mainly focuses on lung and heart diseases.

Its AI platform analyzes medical scans, such as CT scans, to help doctors and researchers understand a patient's condition more quickly and accurately. Qureight works with pharmaceutical companies, hospitals, and research organizations to improve clinical trials and speed up the development of new treatments.

Read Also- Wild Bioscience Acquires F1 Seed to Build a Next-Generation UK Seed Company